Mr To has been a Director since 2000 and an Executive Director and Chairman of HUTCHMED (China) Limited since 2006. He is also a member of the Nomination Committee, Remuneration Committee and Technical Committee of HUTCHMED.
He is the managing director of Hutchison Whampoa (China) Limited ("Hutchison China") and has been with Hutchison China for over 40 years, building its business from a small trading company to a multi-billion dollar investment group. He has negotiated major transactions with multinational corporations such as Procter & Gamble, Lockheed, Pirelli, Beiersdorf, United Airlines, and British Airways. He is currently chairman of Gama Aviation Plc and formerly served as independent non-executive director on the boards of China Southern Airlines Company Limited and Air China Limited. In addition, Mr To is a director of certain substantial shareholders (within the meaning of the Securities and Futures Ordinance) of HUTCHMED and certain companies controlled by substantial shareholders of HUTCHMED.
Mr To’s career in China spans more than 45 years. He is the original founder of the China healthcare business of Hutchison Whampoa Limited (currently a subsidiary of CK Hutchison Holdings Limited) and has been instrumental in its acquisitions made to date. He received a Bachelor’s degree in Mechanical Engineering from Imperial College, London and a Master in Business Administration from Stanford University’s Graduate School of Business.
Dr Su has been an Executive Director since 2017 and Chief Executive Officer of HUTCHMED since March 4, 2022. He is also executive vice president and Chief Scientific Officer of HUTCHMED since 2012. He is also a member of Technical Committee of HUTCHMED. Dr Su has headed all drug discovery and research since he joined HUTCHMED, including master-minding the scientific strategy of HUTCHMED, being a key leader of the Oncology/Immunology operations, and responsible for the discovery of each and every small molecule drug candidate in our pipeline. Prior to joining HUTCHMED in 2005, Dr Su worked with the U.S. research and development department of Pfizer, Inc.
In 2017, Dr Su was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) as one of the Most Influential Drug R&D Leaders in China.
Dr Su received a Bachelor of Science degree in Chemistry from Fudan University in Shanghai and completed a PhD and Post-Doctoral Fellowship in Chemistry at Harvard University under the guidance of Nobel Laureate Professor E. J. Corey.
Mr Cheng has been an Executive Director since 2011 and Chief Financial Officer of HUTCHMED since 2008. He is a member of the Sustainability Committee of HUTCHMED.
Prior to joining HUTCHMED, Mr Cheng was Vice President, Finance of Bristol Myers Squibb in China and was a director of Sino-American Shanghai Squibb Pharmaceuticals Ltd. and Bristol-Myers Squibb (China) Investment Co. Ltd. in Shanghai between late 2006 and 2008.
Mr Cheng started his career as an auditor with Price Waterhouse (currently PricewaterhouseCoopers) in Australia and then KPMG in Beijing before spending eight years with Nestlé China where he was in charge of a number of finance and control functions in various operations. Mr Cheng received a Bachelor of Economics, Accounting Major from the University of Adelaide and is a member of Chartered Accountants Australia and New Zealand.
Dr Eldar has been a Non-executive Director of HUTCHMED since 2016. He has more than 30 years of experience as a senior executive, leading global operations in telecommunications, water, biotech and healthcare. He is an executive director of Hutchison Water Israel Ltd which focuses on large scale projects including desalination, wastewater treatment and water reuse. He was formerly an independent non-executive director of Leumi Card Ltd., a subsidiary of Bank Leumi Le-Israel B.M., one of Israel’s leading credit card companies.
Dr Eldar received a Doctor of Philosophy degree in Government from Harvard University, Master of Arts degree in Government from Harvard University, Master of Arts degree in Political Science and Public Administration from the Hebrew University of Jerusalem and a Bachelor of Arts degree in Political Science from the Hebrew University of Jerusalem.
Mr To has been a Director since 2000 and an Executive Director and Chairman of HUTCHMED (China) Limited since 2006. He is also a member of the Nomination Committee, Remuneration Committee and Technical Committee of HUTCHMED.
He is the managing director of Hutchison Whampoa (China) Limited ("Hutchison China") and has been with Hutchison China for over 40 years, building its business from a small trading company to a multi-billion dollar investment group. He has negotiated major transactions with multinational corporations such as Procter & Gamble, Lockheed, Pirelli, Beiersdorf, United Airlines, and British Airways. He is currently chairman of Gama Aviation Plc and formerly served as independent non-executive director on the boards of China Southern Airlines Company Limited and Air China Limited. In addition, Mr To is a director of certain substantial shareholders (within the meaning of the Securities and Futures Ordinance) of HUTCHMED and certain companies controlled by substantial shareholders of HUTCHMED.
Mr To’s career in China spans more than 45 years. He is the original founder of the China healthcare business of Hutchison Whampoa Limited (currently a subsidiary of CK Hutchison Holdings Limited) and has been instrumental in its acquisitions made to date. He received a Bachelor’s degree in Mechanical Engineering from Imperial College, London and a Master in Business Administration from Stanford University’s Graduate School of Business.
Dr Su has been an Executive Director since 2017 and Chief Executive Officer of HUTCHMED since March 4, 2022. He is also executive vice president and Chief Scientific Officer of HUTCHMED since 2012. He is also a member of Technical Committee of HUTCHMED. Dr Su has headed all drug discovery and research since he joined HUTCHMED, including master-minding the scientific strategy of HUTCHMED, being a key leader of the Oncology/Immunology operations, and responsible for the discovery of each and every small molecule drug candidate in our pipeline. Prior to joining HUTCHMED in 2005, Dr Su worked with the U.S. research and development department of Pfizer, Inc.
In 2017, Dr Su was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) as one of the Most Influential Drug R&D Leaders in China.
Dr Su received a Bachelor of Science degree in Chemistry from Fudan University in Shanghai and completed a PhD and Post-Doctoral Fellowship in Chemistry at Harvard University under the guidance of Nobel Laureate Professor E. J. Corey.
Mr Cheng has been an Executive Director since 2011 and Chief Financial Officer of HUTCHMED since 2008. He is a member of the Sustainability Committee of HUTCHMED.
Prior to joining HUTCHMED, Mr Cheng was Vice President, Finance of Bristol Myers Squibb in China and was a director of Sino-American Shanghai Squibb Pharmaceuticals Ltd. and Bristol-Myers Squibb (China) Investment Co. Ltd. in Shanghai between late 2006 and 2008.
Mr Cheng started his career as an auditor with Price Waterhouse (currently PricewaterhouseCoopers) in Australia and then KPMG in Beijing before spending eight years with Nestlé China where he was in charge of a number of finance and control functions in various operations. Mr Cheng received a Bachelor of Economics, Accounting Major from the University of Adelaide and is a member of Chartered Accountants Australia and New Zealand.
Dr Eldar has been a Non-executive Director of HUTCHMED since 2016. He has more than 30 years of experience as a senior executive, leading global operations in telecommunications, water, biotech and healthcare. He is an executive director of Hutchison Water Israel Ltd which focuses on large scale projects including desalination, wastewater treatment and water reuse. He was formerly an independent non-executive director of Leumi Card Ltd., a subsidiary of Bank Leumi Le-Israel B.M., one of Israel’s leading credit card companies.
Dr Eldar received a Doctor of Philosophy degree in Government from Harvard University, Master of Arts degree in Government from Harvard University, Master of Arts degree in Political Science and Public Administration from the Hebrew University of Jerusalem and a Bachelor of Arts degree in Political Science from the Hebrew University of Jerusalem.
Ms Shih has been a Non-executive Director since 2006, the Company Secretary of HUTCHMED and the company secretary of Group companies since 2000. She is also chairman of the Sustainability Committee of HUTCHMED. She has over 35 years of experience in legal, regulatory, corporate finance, compliance and corporate governance fields. She is also executive director and company secretary of CK Hutchison Holdings Limited ("CKHH"). She has been with the Cheung Kong (Holdings) Limited ("CKH") group since 1989 and with Hutchison Whampoa Limited ("HWL") from 1991 to 2015. Both CKH and HWL became wholly-owned subsidiaries of CKHH in 2015. She has acted in various capacities within the HWL group, including head group general counsel and company secretary of HWL as well as director and company secretary of HWL subsidiaries and associated companies. Ms Shih is in addition a non-executive director of Hutchison Telecommunications Hong Kong Holdings Limited, Hutchison Port Holdings Management Pte. Limited as the trustee-manager of Hutchison Port Holdings Trust and a member of Board of Commissioners of PT Duta Intidaya Tbk. In addition, Ms Shih is a director of certain substantial shareholders (within the meaning of the Securities and Futures Ordinance) of HUTCHMED and certain companies controlled by substantial shareholders of HUTCHMED. The aforementioned companies are either subsidiaries or associated companies of CKHH of which Ms Shih has oversight as director of CKHH. She is the immediate past international president and current member of the Executive Committee of The Chartered Governance Institute ("CGI"), as well as a past president and current chairperson of the Nomination Committee of The Hong Kong Chartered Governance Institute ("HKCGI", formerly known as The Hong Kong Institute of Chartered Secretaries). She is also chairman of the Process Review Panel for the Financial Reporting Council, a panel member of the Securities and Futures Appeals Tribunal and a member of the Hong Kong- Europe Business Council.
Ms Shih is a solicitor qualified in England and Wales, Hong Kong and Victoria, Australia. She is a fellow of both the CGI and HKCGI, holding Chartered Secretary and Chartered Governance Professional dual designations. Ms Shih holds a Bachelor of Science degree and a Master of Arts degree from the University of the Philippines as well as a Master of Arts degree and a Master of Education degree from Columbia University, New York.
Mr Sun has been a Non-executive Director of HUTCHMED since May 2022. He has been the Managing Director and Head of China Healthcare for General Atlantic since 2018, in charge of private equity investment and portfolio management in healthcare and life sciences sectors.
Mr Sun is a director of Adagene Іnc. He was formerly a director of CANbridge Pharmaceuticals Іnc. and Ocumension Therapeutics Іnc.
Before joining General Atlantic, Mr Sun was the Founding Partner of Huatai Healthcare Іnvestment Fund, successfully leading the investment in Mindray Medical, which is listed on Shenzhen Stock Exchange (SZSE:300760). Prior to that, Mr Sun held various investment roles at Credit Suisse and OrbiMed, and a strategy consultant role at McKinsey & Company, all in the healthcare sector.
Mr Sun holds a Bachelor of Science degree in Mathematics and Physics from Tsinghua University. He also holds a Master of Arts degree in neuroscience from the Johns Hopkins University.
Mr Carter has been a senior Independent Non-executive Director of HUTCHMED since 2017. He is also chairman of the Remuneration Committee and a member of the Audit Committee and Technical Committee of HUTCHMED. He has more than 26 years of experience in the pharmaceutical industry. From 2006 to 2016, Mr Carter served in various senior executive roles at Gilead Sciences, Inc. ("Gilead"), a research-based biopharmaceutical company, with the last position as executive vice president, commercial operations. In this role, Mr Carter headed the worldwide commercial organization responsible for the launch and commercialization of all of the products of Gilead. He also worked as a senior executive at GlaxoSmithKline Plc. He is currently a director of Mallinckrodt plc. He is also a director of Immatics N.V. and VectivBio Holding AG. He is chairman of Evox Therapeutics and a retained advisor to several firms active in the life sciences sector. He was formerly a director of Alder Biopharmaceuticals, Inc.
Mr Carter received a degree in Business Studies from the Ealing School of Business and Management (now merged into University of West London) and is a Fellow of the Chartered Institute of Management Accountants in the United Kingdom.
Dr Ferrante has been an Independent Non-executive Director of HUTCHMED since 2017. She is also chairman of the Technical Committee and a member of the Audit Committee of HUTCHMED. She has more than 26 years of experience in the pharmaceutical industry. She was the former chief medical officer and head of research and development of Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. Dr Ferrante previously held senior positions at Millennium Pharmaceuticals, Inc. and its parent company, Takeda Pharmaceutical Company Limited, including chief medical officer and most recently as oncology therapeutic area and Cambridge USA site head. She had also held positions of increasing responsibility at Pfizer, Inc. ("Pfizer") with the last position as vice president, oncology development. Dr Ferrante is currently a member of the board of directors of MacroGenics, Inc., and Cogent Biosciences, Inc. (formerly Unum Therapeutics Inc.). She is also currently a member of the Scientific Advisory Board of Kazia Therapeutics Limited. Dr Ferrante was previously a director of Baxalta Incorporated until it was acquired by Shire plc in 2016 and a director of Progenics Pharmaceuticals, Inc., until it was acquired by Lantheus Holdings, Inc. in 2020. She was previously a member of the Scientific Advisory Board of Trillium Therapeutics Inc. until it was acquired by Pfizer in November 2021.
Dr Ferrante is an author of a number of papers in the field of oncology, an active participant in academic and professional associations and symposia and holder of several patents. Dr Ferrante received a Bachelor of Science degree in Chemistry and Biology from Providence College and a Doctor of Medicine from Georgetown University.
Ms Shih has been a Non-executive Director since 2006, the Company Secretary of HUTCHMED and the company secretary of Group companies since 2000. She is also chairman of the Sustainability Committee of HUTCHMED. She has over 35 years of experience in legal, regulatory, corporate finance, compliance and corporate governance fields. She is also executive director and company secretary of CK Hutchison Holdings Limited ("CKHH"). She has been with the Cheung Kong (Holdings) Limited ("CKH") group since 1989 and with Hutchison Whampoa Limited ("HWL") from 1991 to 2015. Both CKH and HWL became wholly-owned subsidiaries of CKHH in 2015. She has acted in various capacities within the HWL group, including head group general counsel and company secretary of HWL as well as director and company secretary of HWL subsidiaries and associated companies. Ms Shih is in addition a non-executive director of Hutchison Telecommunications Hong Kong Holdings Limited, Hutchison Port Holdings Management Pte. Limited as the trustee-manager of Hutchison Port Holdings Trust and a member of Board of Commissioners of PT Duta Intidaya Tbk. In addition, Ms Shih is a director of certain substantial shareholders (within the meaning of the Securities and Futures Ordinance) of HUTCHMED and certain companies controlled by substantial shareholders of HUTCHMED. The aforementioned companies are either subsidiaries or associated companies of CKHH of which Ms Shih has oversight as director of CKHH. She is the immediate past international president and current member of the Executive Committee of The Chartered Governance Institute ("CGI"), as well as a past president and current chairperson of the Nomination Committee of The Hong Kong Chartered Governance Institute ("HKCGI", formerly known as The Hong Kong Institute of Chartered Secretaries). She is also chairman of the Process Review Panel for the Financial Reporting Council, a panel member of the Securities and Futures Appeals Tribunal and a member of the Hong Kong- Europe Business Council.
Ms Shih is a solicitor qualified in England and Wales, Hong Kong and Victoria, Australia. She is a fellow of both the CGI and HKCGI, holding Chartered Secretary and Chartered Governance Professional dual designations. Ms Shih holds a Bachelor of Science degree and a Master of Arts degree from the University of the Philippines as well as a Master of Arts degree and a Master of Education degree from Columbia University, New York.
Mr Sun has been a Non-executive Director of HUTCHMED since May 2022. He has been the Managing Director and Head of China Healthcare for General Atlantic since 2018, in charge of private equity investment and portfolio management in healthcare and life sciences sectors.
Mr Sun is a director of Adagene Іnc. He was formerly a director of CANbridge Pharmaceuticals Іnc. and Ocumension Therapeutics Іnc.
Before joining General Atlantic, Mr Sun was the Founding Partner of Huatai Healthcare Іnvestment Fund, successfully leading the investment in Mindray Medical, which is listed on Shenzhen Stock Exchange (SZSE:300760). Prior to that, Mr Sun held various investment roles at Credit Suisse and OrbiMed, and a strategy consultant role at McKinsey & Company, all in the healthcare sector.
Mr Sun holds a Bachelor of Science degree in Mathematics and Physics from Tsinghua University. He also holds a Master of Arts degree in neuroscience from the Johns Hopkins University.
Mr Carter has been a senior Independent Non-executive Director of HUTCHMED since 2017. He is also chairman of the Remuneration Committee and a member of the Audit Committee and Technical Committee of HUTCHMED. He has more than 26 years of experience in the pharmaceutical industry. From 2006 to 2016, Mr Carter served in various senior executive roles at Gilead Sciences, Inc. ("Gilead"), a research-based biopharmaceutical company, with the last position as executive vice president, commercial operations. In this role, Mr Carter headed the worldwide commercial organization responsible for the launch and commercialization of all of the products of Gilead. He also worked as a senior executive at GlaxoSmithKline Plc. He is currently a director of Mallinckrodt plc. He is also a director of Immatics N.V. and VectivBio Holding AG. He is chairman of Evox Therapeutics and a retained advisor to several firms active in the life sciences sector. He was formerly a director of Alder Biopharmaceuticals, Inc.
Mr Carter received a degree in Business Studies from the Ealing School of Business and Management (now merged into University of West London) and is a Fellow of the Chartered Institute of Management Accountants in the United Kingdom.
Dr Ferrante has been an Independent Non-executive Director of HUTCHMED since 2017. She is also chairman of the Technical Committee and a member of the Audit Committee of HUTCHMED. She has more than 26 years of experience in the pharmaceutical industry. She was the former chief medical officer and head of research and development of Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. Dr Ferrante previously held senior positions at Millennium Pharmaceuticals, Inc. and its parent company, Takeda Pharmaceutical Company Limited, including chief medical officer and most recently as oncology therapeutic area and Cambridge USA site head. She had also held positions of increasing responsibility at Pfizer, Inc. ("Pfizer") with the last position as vice president, oncology development. Dr Ferrante is currently a member of the board of directors of MacroGenics, Inc., and Cogent Biosciences, Inc. (formerly Unum Therapeutics Inc.). She is also currently a member of the Scientific Advisory Board of Kazia Therapeutics Limited. Dr Ferrante was previously a director of Baxalta Incorporated until it was acquired by Shire plc in 2016 and a director of Progenics Pharmaceuticals, Inc., until it was acquired by Lantheus Holdings, Inc. in 2020. She was previously a member of the Scientific Advisory Board of Trillium Therapeutics Inc. until it was acquired by Pfizer in November 2021.
Dr Ferrante is an author of a number of papers in the field of oncology, an active participant in academic and professional associations and symposia and holder of several patents. Dr Ferrante received a Bachelor of Science degree in Chemistry and Biology from Providence College and a Doctor of Medicine from Georgetown University.
Mr Jack has been an Independent Non-executive Director of HUTCHMED since 2017. He is also chairman of the Audit Committee and a member of the Nomination Committee and Remuneration Committee of HUTCHMED. He has more than 40 years of experience in finance and audit. He retired as partner of PricewaterhouseCoopers in 2006 after a distinguished career with the firm for over 33 years. He is currently an independent non-executive director of The Greenbrier Companies, Inc. (an international supplier of equipment and services to the freight rail transportation markets) and Hutchison Port Holdings Management Pte. Limited as the trustee-manager of Hutchison Port Holdings Trust (a developer and operator of deep water container terminals). He was formerly a director of COSCO SHIPPING Development Co., Ltd. (formerly known as "China Shipping Container Lines Company Limited", an integrated financial services platform principally engaged in vessel and container leasing).
Mr Jack received a Bachelor of Commerce degree from University of New South Wales, Australia and is a Fellow of the Hong Kong Institute of Certified Public Accountants and an Associate of Chartered Accountants Australia and New Zealand.
Professor Mok has been an Independent Non-executive Director of HUTCHMED since 2017. He is also chairman of the Nomination Committee and a member of the Sustainability Committee and Technical Committee of HUTCHMED. Professor Mok has more than 31 years of experience in clinical oncology with his main research interest focusing on biomarker and molecular targeted therapy in lung cancer. He is currently Li Shu Fan Medical Foundation named professor and chairman of department of clinical oncology at The Chinese University of Hong Kong.
Professor Mok has contributed to over 250 articles in international peer reviewed journals, as well as multiple editorials and textbooks. In October 2018, Professor Mok was the first Chinese to be bestowed with the European Society for Medical Oncology (ESMO) Lifetime Achievement Award, one of the most prestigious international honors and recognitions given to cancer researchers, for his contribution to and leadership in lung cancer research worldwide.
Professor Mok is a non-executive director of AstraZeneca PLC, a board director of the American Society of Clinical Oncology ("ASCO") and a steering committee member of the Chinese Society of Clinical Oncology ("CSCO"). He is also currently chairman of the board of ACT Genomics Holdings Ltd. ("ACT Genomics") and a non-executive independent director of Lunit USA Inc. He is past president of the International Association for the Study of Lung Cancer, and co-founder of Sanomics Limited (acquired by ACT Genomics in November 2021) and Aurora Tele-Oncology Limited. Professor Mok is also closely affiliated with the oncology community in China and has been awarded an Honorary Professorship at Guangdong Province People’s Hospital, Guest Professorship at Peking Union Medical College Hospital and Visiting Professorship at Shanghai Jiao Tong University. He received his Bachelor of Medical Science degree and a Doctor of Medicine from University of Alberta, Canada. He is also a fellow of the Royal College of Physicians and Surgeons of Canada, Hong Kong College of Physicians, Hong Kong Academy of Medicine, Royal College of Physicians of Edinburgh and ASCO.
Mr Jack has been an Independent Non-executive Director of HUTCHMED since 2017. He is also chairman of the Audit Committee and a member of the Nomination Committee and Remuneration Committee of HUTCHMED. He has more than 40 years of experience in finance and audit. He retired as partner of PricewaterhouseCoopers in 2006 after a distinguished career with the firm for over 33 years. He is currently an independent non-executive director of The Greenbrier Companies, Inc. (an international supplier of equipment and services to the freight rail transportation markets) and Hutchison Port Holdings Management Pte. Limited as the trustee-manager of Hutchison Port Holdings Trust (a developer and operator of deep water container terminals). He was formerly a director of COSCO SHIPPING Development Co., Ltd. (formerly known as "China Shipping Container Lines Company Limited", an integrated financial services platform principally engaged in vessel and container leasing).
Mr Jack received a Bachelor of Commerce degree from University of New South Wales, Australia and is a Fellow of the Hong Kong Institute of Certified Public Accountants and an Associate of Chartered Accountants Australia and New Zealand.
Professor Mok has been an Independent Non-executive Director of HUTCHMED since 2017. He is also chairman of the Nomination Committee and a member of the Sustainability Committee and Technical Committee of HUTCHMED. Professor Mok has more than 31 years of experience in clinical oncology with his main research interest focusing on biomarker and molecular targeted therapy in lung cancer. He is currently Li Shu Fan Medical Foundation named professor and chairman of department of clinical oncology at The Chinese University of Hong Kong.
Professor Mok has contributed to over 250 articles in international peer reviewed journals, as well as multiple editorials and textbooks. In October 2018, Professor Mok was the first Chinese to be bestowed with the European Society for Medical Oncology (ESMO) Lifetime Achievement Award, one of the most prestigious international honors and recognitions given to cancer researchers, for his contribution to and leadership in lung cancer research worldwide.
Professor Mok is a non-executive director of AstraZeneca PLC, a board director of the American Society of Clinical Oncology ("ASCO") and a steering committee member of the Chinese Society of Clinical Oncology ("CSCO"). He is also currently chairman of the board of ACT Genomics Holdings Ltd. ("ACT Genomics") and a non-executive independent director of Lunit USA Inc. He is past president of the International Association for the Study of Lung Cancer, and co-founder of Sanomics Limited (acquired by ACT Genomics in November 2021) and Aurora Tele-Oncology Limited. Professor Mok is also closely affiliated with the oncology community in China and has been awarded an Honorary Professorship at Guangdong Province People’s Hospital, Guest Professorship at Peking Union Medical College Hospital and Visiting Professorship at Shanghai Jiao Tong University. He received his Bachelor of Medical Science degree and a Doctor of Medicine from University of Alberta, Canada. He is also a fellow of the Royal College of Physicians and Surgeons of Canada, Hong Kong College of Physicians, Hong Kong Academy of Medicine, Royal College of Physicians of Edinburgh and ASCO.